Select your Background Color
add
add longest videos

JNJ-7925476 is a TRI antidepressant currently under development by Johnson & Johnson.

These molecules were first prepared by Bruce E. Maryanoff, et al. during the late 1970s – 1980's. and is known as a pyrroloisoquinoline, that is benzhydryl-containing.

Incorporating the pyrrolidino ring onto the THIQ scaffolding markedly improves potency, although this only works for one of the available diastereo/enantiomers. JNJ-7925476 is a racemic preparation of the more potent diastereomer. The eutomer, JNJ-39836966 has (6R,10bS)-stereochemistry whereas the distomer JNJ-39836732 will have (6S,10bR)-stereochemistry.

The compounds depicted appear to be cis but Maryanoff and coworkers are of the opinion that it is trans. (see abstract)

The reason for this is not known because it was referred to as "cis" to begin with, only reassigning it later.

Cyclohexane conformation

Ki values (nM) for JNJ-7925476 and its constituent enantiomers (JNJ-39836966 and JNJ-39836732)

In vitro, JNJ-7925476 is ~18-fold selective for the hSERT (0.9 nM) over the hNET (16.6 nM).

Read more...



This page contains text from Wikipedia, the Free Encyclopedia - http://en.wikipedia.org/wiki/JNJ-7925476

This article is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License, which means that you can copy and modify it as long as the entire work (including additions) remains under this license.









×
×